JP2022506109A5 - - Google Patents

Info

Publication number
JP2022506109A5
JP2022506109A5 JP2021523277A JP2021523277A JP2022506109A5 JP 2022506109 A5 JP2022506109 A5 JP 2022506109A5 JP 2021523277 A JP2021523277 A JP 2021523277A JP 2021523277 A JP2021523277 A JP 2021523277A JP 2022506109 A5 JP2022506109 A5 JP 2022506109A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
subject
blood
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021523277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022506109A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/058898 external-priority patent/WO2020092594A1/en
Publication of JP2022506109A publication Critical patent/JP2022506109A/ja
Publication of JP2022506109A5 publication Critical patent/JP2022506109A5/ja
Pending legal-status Critical Current

Links

JP2021523277A 2018-10-30 2019-10-30 治療用化合物および組成物 Pending JP2022506109A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752510P 2018-10-30 2018-10-30
US62/752,510 2018-10-30
PCT/US2019/058898 WO2020092594A1 (en) 2018-10-30 2019-10-30 Therapeutic compounds and compositions

Publications (2)

Publication Number Publication Date
JP2022506109A JP2022506109A (ja) 2022-01-17
JP2022506109A5 true JP2022506109A5 (cg-RX-API-DMAC10.html) 2022-10-28

Family

ID=70464743

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523277A Pending JP2022506109A (ja) 2018-10-30 2019-10-30 治療用化合物および組成物

Country Status (10)

Country Link
US (1) US20210253550A1 (cg-RX-API-DMAC10.html)
EP (1) EP3873446A4 (cg-RX-API-DMAC10.html)
JP (1) JP2022506109A (cg-RX-API-DMAC10.html)
KR (1) KR20210084581A (cg-RX-API-DMAC10.html)
CN (1) CN113056263A (cg-RX-API-DMAC10.html)
AU (1) AU2019369518A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021008462A2 (cg-RX-API-DMAC10.html)
CA (1) CA3117549A1 (cg-RX-API-DMAC10.html)
IL (1) IL282765A (cg-RX-API-DMAC10.html)
WO (1) WO2020092594A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499532B2 (en) 2014-02-07 2016-11-22 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions
WO2019156929A1 (en) 2018-02-07 2019-08-15 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions
TW202345825A (zh) * 2022-03-30 2023-12-01 大陸商四川海思科製藥有限公司 環狀內醯胺類化合物的注射用藥物組合物及其製備方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
CA2648522A1 (en) * 2005-04-04 2006-10-12 Daiamed, Inc. Substituted azetidinones
LT2766346T (lt) * 2011-10-14 2017-06-12 Bristol-Myers Squibb Company Pakeistieji tetrahidroizochinolino junginiai, kaip faktoriaus xia inhibitoriai
US9499532B2 (en) * 2014-02-07 2016-11-22 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions
US20190315711A1 (en) * 2016-12-23 2019-10-17 Exithera Pharmaceuticals, Inc. Therapeutic compounds and compositions
CA3117470A1 (en) * 2018-10-30 2020-05-07 Exithera Pharmaceuticals, Inc. Therapeutic compounds and compositions
KR20210119432A (ko) * 2019-01-29 2021-10-05 엑시테라 파마슈티컬스 인코퍼레이티드 치료 화합물 및 조성물

Similar Documents

Publication Publication Date Title
JP2022506110A5 (cg-RX-API-DMAC10.html)
Blake et al. The use of dual lumen jugular venous catheters as definitive long term access for haemodialysis
JP2022523712A5 (cg-RX-API-DMAC10.html)
WO1996032074A1 (en) Method of treating cardiac arrest
SU1183112A1 (ru) Способ лечени острой ишемии миокарда
Buchanan Sulphamethoxazole, hypoalbuminaemia, crystalluria, and renal failure
Sim et al. A fatal case of iatrogenic hypercalcemia after calcium channel blocker overdose
Gaynor Use of modified ultrafiltration after repair of congenital heart defects
Rottembourg et al. Clinical aspects of continuous ambulatory and continuous cyclic peritoneal dialysis in diabetic patients
Dickson et al. Continuous renal replacement in the critically ill
Kaplan Continuous renal replacement therapy (CRRT) in the intensive care unit
Seltzer et al. Decrease in arterial pressure following heparin injection prior to cardiopulmonary bypass
Morgan et al. Fluid removal by haemofiltration in diuretic resistant cardiac failure.
Vaziri et al. Hemodialysis clearance of cimetidine
Darling et al. Modified ultrafiltration in pediatric cardiopulmonary bypass
Clar et al. Hemofiltration: determinants of drug loss and concentration
Hwang et al. Dialytic ascitic ultrafiltration in refractory ascites.
RU2021115313A (ru) Терапевтические соединения и композиция
Khanna et al. Peritoneal dialysis in diabetic end-stage renal disease
Mendeloff et al. Thromboxane A2 receptor-specific antagonism in hypothermic cardiopulmonary bypass
US3632765A (en) Treatment of shock
Caruso et al. Continuous hemodialysis for the management of acute renal failure in the presence of cerebellar hemorrhage: case report
Dorsey Venoarterial bypass in hypothermia
Cramer II et al. Technical aspects of pediatric continuous renal replacement therapy
Kopman Scavenging of potassium cardioplegic solution to prevent hyperkalemia in hemodialysis-dependent patients